GlassScriptPhysician profile
Randy W Charrier
NPI 1124270582
$15,367.49
in general payments reported to CMS, 2019-2025
21 companies · $5,276 in 2025
The $5,276 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $210 · 2021: $6,815 · 2022: $695 · 2023: $1,193 · 2024: $474 · 2025: $5,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450 · Food and Beverage: $2,067 · Honoraria: $1,900 · Gift: $488 · Entertainment: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
| Food and Beverage | $2,066.64 |
| Honoraria | $1,900.00 |
| Gift | $487.50 |
| Entertainment | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionary Optics LLC | $7,005.50 | 2019-2025 | |
| Heidelberg Engineering, INC. | $4,367.10 | 2024-2025 | Spectralis |
| Sun Pharmaceutical Industries INC. | $1,171.67 | 2019-2025 | Cequa |
| Alcon Vision LLC | $546.05 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Dompe US, INC. | $454.91 | 2019-2025 | Oxervate |
| Glaukos Corporation | $351.53 | 2021-2023 | |
| Oyster Point Pharma, INC. | $252.63 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $221.56 | 2019-2022 | |
| Optos, INC. | $131.96 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $120.85 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $119.33 | 2023 | |
| Abbvie INC. | $112.04 | 2022-2023 | Lumigan |
| Bausch & Lomb Americas INC. | $106.38 | 2023-2024 | Vyzulta, Zylet, Alrex |
| Shire North American Group INC | $90.41 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $77.62 | 2024-2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heru, INC. | $69.50 | 2022 | |
| Biotissue Holdings INC. | $65.69 | 2024-2025 | |
| Abb Con-Cise Optical Group LLC | $30.86 | 2025 | Contact Lens |
| Carl Zeiss Meditec USA, INC. | $26.05 | 2023 | Atlas Corneal Topography System |
| Johnson & Johnson Vision Care, INC. | $23.77 | 2020 | |
| Coopervision INC. | $22.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Charrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.